- Phibro Animal Health Corporation (NASDAQ: PAHC) is set to release its Q3 2026 financial results on May 6, 2026, with an investor webcast to follow.
- CEO BENDHEIM JACK recently sold 5,805 shares for $52.65 each, reducing his stake to 75,995 shares.
- The company exhibits robust financial health with a P/E ratio of 24.07, a debt-to-equity ratio of 2.33, and a strong current ratio of 3.05.
Phibro Animal Health Corporation (NASDAQ: PAHC) is a prominent company in the animal health industry that develops and sells a wide range of animal health and mineral nutrition products. These essential products cater to food animals, including poultry, swine, and cattle. The company operates in a competitive market alongside other large animal health firms.
Phibro Animal Health Corporation announced it will release its third-quarter financial results for 2026 on Wednesday, May 6, after the market closes. Following this highly anticipated release, the company’s management will host a webcast and conference call. This investor call is scheduled for Thursday, May 7, 2026, at 9:00 AM Eastern Time to discuss the financial performance update.
Leading up to the earnings report, company President and CEO BENDHEIM JACK executed an executive stock sale, selling 5,805 shares on April 30, 2026. The shares were sold at a price of $52.65 each. After this transaction, the CEO’s remaining ownership in the company stands at 75,995 shares, reflecting recent shareholder activity.
Analysts expect Phibro Animal Health Corporation to report earnings per share (EPS) of $0.72. EPS is a key metric that shows how much profit the company generates for each share of its stock. The consensus estimate for revenue is approximately $367.02 million. Investors will closely watch the upcoming release to see if the actual financial results meet these analyst expectations.
The company’s current price-to-earnings (P/E) ratio, a crucial stock valuation metric, is 24.07. This ratio values a company by its current share price relative to its per-share earnings. For overall financial health, its debt-to-equity ratio is 2.33, while its current ratio of 3.05 indicates a strong ability to meet short-term obligations, providing positive investment insights.
